Brian T. Powl, Chief Commercial Officer of Kura Oncology Inc., sold 4,345 shares of the company’s common stock on August 21 for a total of $51,663, according to a regulatory filing.
The transaction was executed at prices ranging from $11.78 to $12.00 per share, with a weighted average sale price of $11.8903. The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2025. Following the sale, Powl retains a direct and beneficial ownership of 169,269 shares.
Kura Oncology’s shares have gained 62% over the past year, reaching a 52-week high of $12.90. The company reported adjusted loss per share of $0.77 in the second quarter of 2026, outperforming the anticipated loss of $0.88, while revenue totaled $20.87 million, exceeding the expected $20.16 million. Analysts at Citizens reiterated a Market Outperform rating with a $24.00 price target.
The company’s recent performance has been supported by early sales of its newly launched cancer drug, KOMZIFTI. Separately, Kura Oncology’s President and CEO Troy Edward Wilson purchased 100,000 shares at an average price of $11.12 per share, as disclosed in an SEC filing.
